Scientists hunt for clues to improve leukemia treatment after transplant

NCT ID NCT07627568

Recruiting now Knowledge-focused Sponsor: University of Freiburg Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers will measure certain biomarkers to see if they relate to how well the leukemia responds or how long patients survive. The goal is to learn more, not to test a new treatment directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: menin inhibitor
What this could lead to: If successful, this could help identify which patients might respond to menin inhibitors after a stem cell transplant, potentially guiding future treatment decisions.
What could go wrong: This is a very small, early biomarker study with only 20 participants. It is not designed to test whether the treatment works, only to look for biological signals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia with mutated NPM1 acute myeloid leukemia, MLL gene rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA AML WITH NPM1 MUTATIONS OR KMT2A REARRANGEMENTS

Contacts and locations

Locations

University of Freiburg Mdical Center
RECRUITING

Freiburg im Breisgau, 79106, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.